Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.
According to Zacks, "Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function.
* Galectin Therapeutics Inc- on track for reporting of top-line results in december of 2017 for nash-cx trial
NORCROSS, Ga., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announces interim results from an exploratory, open-label, Phase 2a clinical trial with...
In an initial closing, Galectin Therapeutics Inc. (carbohydrate-based therapies for fibrotic liver disease and cancer based on understanding of galectin proteins) sold 375k shares (of a potential 1.5mm shares) of Series B-3 convertible preferred stock and warrants to purchase 104k common shares to 10X Fund for gross proceeds of $375k.
* Galectin Therapeutics announces $4 million in new equity financings
* Richard Uihlein reports 7.89 percent stake in Galectin Therapeutics Inc as of Dec 22 - SEC filing Source text: (http://bit.ly/2jMCBRA) Further company coverage:
Galectin Therapeutics has reported disappointing results from a mid-stage study of its candidate compound…
Galectin Therapeutics Inc. (carbohydrate-based therapies for fibrotic liver disease and cancer based on understanding of galectin proteins) raised $3mm through the sale of 2.8mm common shares and 2.1mm common stock purchase warrants (strike price of $5). The offering was sold in units with each unit consisting of one common share and one seven-year warrant to purchase 0.75 of a common share at a ...
* Galectin Therapeutics announces positive new psoriasis and atopic dermatitis clinical data, seeking strategic partnerships for therapy of severe skin diseases Source text for Eikon: Further company coverage:
Galectin Therapeutics Inc (NASDAQ:GALT) won’t pursue GR-MD-02 as a drug for psoriasis after patients in a small trial did not show the required improvement. The drug developer added, however, that the results did give it encouragement for its liver fibrosis program, which is the drug’s primary focus. Galectin started the small study after a patient taking the drug in a tr...
Project Synopsis:Datamonitor's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.Project Description:Datamonitors' Galectin Therapeutics, Inc. formerly ProPharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Allianc...
BBI Solutions has announced the launch of a range of antibodies for the biomarker Galectin-3. The antibodies complement BBI’s Galectin-3 antigen, which was also launched earlier this year.
Shares in the biotech nearly halved in value Wednesday, as investors soured on the potential of Galectin's lead drug after it failed to hit its goal in a Phase 2a study.
Galectin Therapeutics (NASDAQ:GALT) has completed patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis, the NASH-CX trial. The company expects to report the topline results of the trial in December 2017. “We are pleased that patient recruitment in our NASH-CX trial was completed ahead of our original […]
The new study examines the biomechanics of galectin-3's interaction with glycosaminoglycans (GAG) and proteoglycans. Tarun Dam, an associate professor of chemistry at Michigan Technological University, led the study. The other co-authors of the paper are graduate students Melanie Talaga, Ni Fan, ...
* Galectin therapeutics announces top-line data from exploratory phase 2a pilot trial (nash-fx) with gr-md-02 in nash patients with advanced fibrosis
Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September Australian patent allowance strengthens global intellectual property franchise NORCROSS, Ga., Aug. 09, 2016 (GLOBE NEWSWIRE) Read more...
* Says announces results from 12-week extension of phase 2A psoriasis clinical trial - SEC Filing
Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled Closed private placement financing for $1.5 million Conference call to be held today at 5:30 p.m. (Eastern Time) NORCOSS, Ga., Sept. 27, 2016 (GLOBE NEWSWIRE) Read more...
SummaryGalectin Therapeutics Inc Galectin Therapeutics, formerly ProPharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company's products comprise GRMD02 and GMCT01. Its GRMD02 is a drug candidate used for treating fibrotic liver disease. Its GMCT01 is a vaccine used to treat patients with advanced melanoma, a...
As big pharma races to develop a treatment for the liver disease non-alcoholic steatohepatitis (NASH), biotech Galectin suffered a blow as its potential treatment failed in a mid-stage clinical trial. Galectin said its phase 2a NASH-FX trial evaluating GR-MD-02 in 30 NASH patients with advanced fibrosis failed to meet its endpoint. The exploratory four month long randomised study did not meet it...
SummaryGalectin Therapeutics, Inc. Galectin Therapeutics is a biotechnology company that offers therapies. The company discovers, develops and commercializes therapies for fibrotic disease and cancer. Its products include GRMD02 and GMCT01. The company's GRMD02 is a drug candidate used in the treatment of fibrotic liver disease. Galectin Therapeutics's GMCT01 is a vaccine used to treat patients wi...